Jung-Woo Park

发表

Cardioprotective effects of the novel Na+/H+ exchanger-1 inhibitor KR-32560 in a perfused rat heart model of global ischemia and reperfusion: Involvement of the Akt-GSK-3β cell survival pathway and antioxidant enzyme

K. Yi, S. Yoo, W. Choi, 2010, Archives of pharmacal research.

Cardioprotective Effects of [5-(2-Methyl-5-Fluorophenyl)furan-2-ylcarbonyl]guanidine (KR-32568) in an Anesthetized Rat Model of Ischemia and Reperfusion Heart Injury

K. Yi, Y. Yun, S. Yoo, 2005, Pharmacology.

BMS-191095, a cardioselective mitochondrial katp opener, inhibits human platelet aggregation by opening mitochondrial katp channels

K. Yi, Y. Yun, S. Yoo, 2005, Archives of pharmacal research.

Effects of [5-(2-methoxy-5-fluorophenyl)furan-2-ylcarbonyl]guanidine (KR-32560), a novel sodium/hydrogen exchanger-1 inhibitor, on myocardial infarct size and ventricular arrhythmias in a rat model of ischemia/reperfusion heart injury.

K. Yi, Y. Yun, S. Yoo, 2005, Journal of pharmacological sciences.

15,16-Dihydrotanshinone I, a major component from Salvia miltiorrhiza Bunge (Dansham), inhibits rabbit platelet aggregation by suppressing intracellular calcium mobilization

Jung-Jin Lee, Hyung-Sik Won, H. Won, 2008, Archives of pharmacal research.

A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30‐Minute Intravenous Infusion in Patients With Cancer

M. Borad, D. Northfelt, P. Lebowitz, 2010, Journal of clinical pharmacology.

Antiplatelet activity of [5-(2-methoxy-5-chlorophenyl)furan-2-ylcarbonyl]guanidine (KR-32570), a novel sodium/hydrogen exchanger-1 and its mechanism of action

K. Yi, Y. Yun, Yong-ri Jin, 2006, Archives of pharmacal research.

Evaluation of nitroglycerin and cyclosporin A sorption to polyvinylchloride- and non-polyvinylchloride-based tubes in administration sets

Su-Eon Jin, Sang Wook Park, Seungho Jeon, 2018, Journal of Pharmaceutical Investigation.

A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30‐Minute Intravenous Infusion in Patients With Cancer

M. Borad, D. Northfelt, P. Lebowitz, 2010, Journal of clinical pharmacology.